In the Tropics-02 study, a randomised phase III trial, SG was compared with physician’s choice chemotherapy (eribulin, vinorelbine, capecitabine or gemcitabine) in the HR+/HER2– breast cancer patients with endocrine-resistant, chemotherapy-treated (19). This evidence concerns the gene ERBB2 and breast carcinoma.